GlaxoSmithKline's ($GSK) lung drug Anoro Ellipta, key to rebuilding its respiratory franchise after megablockbuster Advair meets generic competition, won recommendation from European authorities. The combination treatment for chronic obstructive pulmonary disease (COPD) is expected to hit $2 billion in sales by 2018. Report